Table 2.
Medications and comorbidities of the patients by group (n = 257).
| Non-statin group (n = 167) | Statin group (n = 90) | p-Value | |
|---|---|---|---|
| Comorbidities | |||
| COPD | 46 (27.5) | 28 (31.1) | 0.547 |
| Hypertension | 110 (65.8) | 70 (77.7) | 0.047 |
| Diabetes | 49 (29.3) | 37 (41.1) | 0.056 |
| Malignancy | 33 (19.7) | 15 (16.6) | 0.544 |
| Coronary artery disease | 37 (22.1) | 47 (52.2) | <0.001 |
| Cerebrovascular disease | 32 (19.1) | 23 (25.5) | 0.233 |
| Chronic renal failure | 12 (7.1) | 7 (7.7) | 0.863 |
| Chronic heart failure | 21 (12.5) | 17 (18.8) | 0.174 |
| Chronic liver disease | 10 (5.9) | 1 (1.1) | 0.065 |
| Peripheral vascular disease | 6 (3.5) | 6 (6.6) | 0.265 |
| Preadmission medication | |||
| ACE I or angiotensin II antagonists | 28 (16.7) | 24 (26.6) | 0.059 |
| Aspirin | 30 (17.9) | 30 (33.3) | 0.005 |
| Beta blockers | 17 (10.1) | 22 (24.4) | 0.002 |
| Calcium antagonists | 43 (25.7) | 34 (37.7) | 0.045 |
| Antiplatelet agents (other) | 19 (11.3) | 31 (34.4) | <0.001 |
| Spironolactone | 20 (11.9) | 9 (10.0) | 0.633 |
| Furosemide | 17 (10.1) | 9 (10.0) | 0.964 |
| Nitrate esters | 23 (13.7) | 22 (24.4) | 0.032 |
| Oral hypoglycemics | 22 (13.1) | 27 (30.0) | 0.001 |
| Digoxin | 14 (8.3) | 9 (10.0) | 0.665 |
| Trimetazidine | 14 (8.3) | 28 (31.1) | <0.001 |
| Antiarrhythmic agents | 5 (2.9) | 8 (8.8) | 0.040 |
| Insulin | 9 (5.3) | 8 (8.8) | 0.282 |
| Warfarin | 5 (2.9) | 2 (2.2) | 0.717 |
| Donepezil hydrochloride | 8 (4.7) | 4 (4.4) | 0.900 |
| Memantine | 6 (3.5) | 2 (2.2) | 0.546 |
| Steroid use for chronic diseases | 3 (1.7) | 3 (3.3) | 0.436 |
Abbreviations: COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitors.
Data are shown as n (%).